Latest news with #EEST
Yahoo
23-05-2025
- Business
- Yahoo
WithSecure Corporation – Managers' Transactions – Kerkelä-Hiltunen
WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers' Transactions – Kerkelä-Hiltunen WithSecure Corporation - Managers' transactions - Kerkelä-Hiltunen____________________________________________ Person subject to the notification requirementName: Kerkelä-Hiltunen, MerviPosition: Member of the Board/Deputy memberIssuer: WithSecure CorporationLEI: 743700ATXLT0MFCHXT16 Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20250522123005_37____________________________________________ Transaction date: 2025-05-21Venue not applicableInstrument type: SHAREISIN: FI4000519228Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 20335 Unit price: 0.00 EUR Aggregated transactions(1): Volume: 20335 Volume weighted average price: 0.00 EUR Contact information: Laura ViitaVP, Controlling, investor relations and sustainabilityWithSecure Corporation +358 50 487 1044 investor-relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
WithSecure Corporation – Managers' Transactions
WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers' Transactions – Syrjänen WithSecure Corporation - Managers' transactions - Syrjänen____________________________________________ Person subject to the notification requirementName: Syrjänen, TuomasPosition: Member of the Board/Deputy memberIssuer: WithSecure CorporationLEI: 743700ATXLT0MFCHXT16 Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20250522123005_33____________________________________________ Transaction date: 2025-05-21Venue not applicableInstrument type: SHAREISIN: FI4000519228Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 20335 Unit price: 0.00 EUR Aggregated transactions(1): Volume: 20335 Volume weighted average price: 0.00 EUR Contact information: Laura ViitaVP, Controlling, investor relations and sustainabilityWithSecure Corporation +358 50 487 1044 investor-relations@
Yahoo
12-05-2025
- Business
- Yahoo
KH Group: Indoor continues profitability improvement measures – the company will start change negotiations
KH Group PlcPress Release 12 May 2025 at 12:00 noon EEST KH Group: Indoor continues profitability improvement measures – the company will start change negotiations As a profitability improvement measure, Indoor Group will commence change negotiations in accordance with the Act on Co-operation in Undertakings covering employees in the support functions of Indoor and Insofa. The change negotiations will begin on 19 May 2025 and the scope of the negotiations will cover 84 employees. The number and targeting of possible layoffs and dismissals will be specified during the negotiations. The change negotiations seek measures to improve profitability by approximately EUR 2 million. The measures are part of an extensive operating model reform, which aims for an annual operating profit improvement of at least EUR 10 million by the end of 2026. 'Our aim is to renew management model, reorganize functions and improve profitability to build a solid foundation for the future of Indoor Group', says Kati Kivimäki, CEO of Indoor Group. 'During the first quarter, Indoor Group made an operating loss of EUR 2,5 million and in this situation these measures to improve profitability are necessary', adds Ville Nikulainen, CEO of KH Group. KH GROUP PLC Further information:CEO Ville Nikulainen, tel. +358 40 045 9343Indoor Group CEO Kati Kivimäki, tel. +358 46 876 1500 Distribution:Major KH Group Plc is a Nordic conglomerate operating in the business areas of KH-Koneet, Nordic Rescue Group and Indoor Group. We are a leading supplier of construction and earth-moving equipment, rescue vehicle manufacturer as well as furniture and interior decoration retailer. The objective of our strategy is to create an industrial group around the business of KH-Koneet. KH Group's share is listed on Nasdaq Helsinki.
Yahoo
07-05-2025
- Business
- Yahoo
Release of Marimekko's Interim Report, 1 January–31 March 2025
Marimekko Corporation Marimekko Corporation, Press release 7 May 2025 at 11.00 a.m. EEST Release of Marimekko's Interim Report, 1 January–31 March 2025 Marimekko Corporation's Interim Report 1 January–31 March 2025 will be published on Wednesday 14 May 2025 at 8.00 a.m. EEST. The report and related materials will be available on the company's website at after the publication. A media and investor conference will be held in English on 14 May 2025 at 2.00 p.m. EEST. A live webcast of the conference can be followed at and a recording of the webcast will be available at the same address later. Questions can be asked during the live webcast in writing. Additional information: Anna Tuominen, Marimekko Communications Tel. +358 40 584 6944 DISTRIBUTION: Key media Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company's product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. In 2024, the company's net sales totaled EUR 183 million and comparable operating profit margin was 17.5 percent. Globally, there are roughly 170 Marimekko stores, and online store serves customers in 39 countries. The key markets are Northern Europe, the Asia-Pacific region and North America. The Group employs about 480 people. The company's share is quoted on Nasdaq Helsinki Ltd.
Yahoo
23-04-2025
- Business
- Yahoo
Orion Group Interim Report January–March 2025
ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST Orion Group Interim Report January–March 2025 January–March 2025 Highlights Net sales totalled EUR 354.6 (January–March 2024: 308.5) million Operating profit was EUR 77.9 (56.0) million Basic earnings per share were EUR 0.44 (0.31) Cash flow from operating activities per share was EUR 0.55 (0.78) Outlook for 2025 remains unchanged: Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million. Key figures1–3/25 1–3/24 Change % 1–12/24 Net sales, EUR million 354.6 308.5 +14.9% 1,542.4 EBITDA, EUR million 91.5 68.5 +33.6% 509.4 % of net sales 25.8% 22.2% 33.0% Operating profit, EUR million 77.9 56.0 +39.1% 416.6 % of net sales 22.0% 18.2% 27.0% Profit before taxes, EUR million 76.8 54.9 +39.9% 413.1 % of net sales 21.7% 17.8% 26.8% Profit for the period, EUR million 61.3 43.8 +39.9% 329.9 % of net sales 17.3% 14.2% 21.4% Research and development expenses, EUR million 41.0 36.8 +11.3% 179.6 % of net sales 11.6% 11.9% 11.6% Capital expenditure, EUR million 20.5 13.1 +56.7% 86.1 % of net sales 5.8% 4.2% 5.6% Interest-bearing net liabilities, EUR million 61.8 6.4 > 100 % 121.7 Basic earnings per share, EUR 0.44 0.31 +39.8% 2.35 Cash flow from operating activities per share, EUR 0.55 0.78 -29.7% 2.09 Equity ratio, % 62.9% 48.8% 61.9% Gearing, % 5.8% 0.9% 12.1% Return on capital employed (before taxes), % 23.4% 22.8% 34.9% Return on equity (after taxes), % 23.7% 21.9% 34.8% Average number of personnel during the period 3,928 3,673 +7.0% 3,712President and CEO Liisa Hurme: Strong start for the year "In January–March 2025, our net sales increased by 14.9 percent to EUR 354.6 (308.5) million and operating profit increased by 39.1 percent to EUR 77.9 (56.0) million. The year 2025 has started strongly with almost all business divisions reporting good growth. Nubeqa® continued to drive the growth of the Group and the Innovative Medicines business division. Both royalty income and product sales increased significantly from the comparison period. In addition, Nubeqa®'s product sales grew from the previous quarter and were at an all-time high so far. In Branded Products, all therapy areas grew nicely. Starting from this reporting period, we will split the division's net sales by three therapeutic areas. Each therapy area's strategy is to build business around one key product group. In Respiratory, the key product group is Easyhaler® product portfolio, in CNS entacapone products and in Women's Health Divina® series. Generics and Consumer Health and Animal Health business divisions also continued their growth path as expected in the first quarter of 2025. The decline in Fermion's external net sales from the comparison period is explained by the allocation of capacity more to internal use, as well as by timing of deliveries. Operating profit grew again significantly faster than net sales, which is mostly explained by the growth of Nubeqa® royalties and product sales, but also by the good development of the rest of the business. The growth of Nubeqa® royalties was strong, especially considering the fact that, as usual, the previous quarter's product sales, which were very good at the end of 2024, have been deducted from the royalty. Operating expenses increased but were lower than we anticipated. Sales and marketing expenses were increased by, among other things, investments in the promotion of the Easyhaler® product portfolio, as well as the Japanese sales office established last year. The increase in research and development costs is explained by the progress of clinical development projects and the research portfolio, where the costs of biological medicines, in particular, increase significantly as they approach the clinical development stage. US import tariffs continue to be a hot topic worldwide, and there is a lot of uncertainty around the topic right now. The United States is an important market for Orion, and we will, of course, follow the development of the situation closely. In March, we announced that Orion is establishing a new research & development centre in Cambridge, UK during 2025. With this we aim to accelerate our global growth strategy and the development of innovative medicines. The new centre will focus on the pharmaceutical development of new biological and large-molecule therapies. Orion's own clinical development projects progressed as planned during the early part of the year. In addition, we have added to Orion's list of key clinical development projects a Phase 3 project, in which our partner Tenax develops oral levosimendan for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction. Tenax has announced that it will increase the number of patients in the ongoing study and plans to start during 2025 a second phase III study which is aiming for global registration. With these advances, we felt the time was right to include Tenax Phase III projects with levosimendan in Orion's research pipeline. The original license agreement with Tenax (formerly Phyxius) was signed already in 2013. All in all, the year 2025 has started very well and from here it is good to continue this year forward together with all Orionees and numerous partners.' Outlook for 2025 Net sales are estimated to be EUR 1,550 million to EUR 1,650 million. Operating profit is estimated to be EUR 350 million to EUR 450 million. Webcast and Conference Call A webcast and a conference call for analysts, investors and media representatives will be held on Wednesday, 23 April 2025 at 13.30 EEST. A link to the live webcast is available on Orion's website at A recording of the event will be available on the website later the same day. Conference call can be joined by registering through the following link: Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue. Questions can also be presented in writing through the question form of the webcast. Upcoming events Capital Markets Day 2025 Thursday 22 May 2025 Half-Year Financial Report January–June 2025 Friday 18 July 2025 Interim Report January–September 2025 Tuesday 28 October 2025 Espoo, 23 April 2025 Board of Directors of Orion Corporation For additional information about the report: Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 or +358 50 966 2721 Publisher: Orion Corporation Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Attachment Orion Interim Report Q1 2025Sign in to access your portfolio
